Ann: Orthocell Appoints Non-Executive Director Dr Ravi Thadhani, page-43

Speckled, my sentiments exactly.

I honestly thought professional money would come on board with the BH deal. I get bored of hearing myself say it (and I am sure others do), but PA & Prof MZ sold some of the rights (OCC clearly retains some) of ACI to Vericel for $55 million and even in its infancy as a US company it is already knocking out MACI at $30+ million revenue per quarter! OCC can offer CelGro in a multitude of approved functions, ATI and ACI. Its potential is huge, and this management team finally starting to commercially execute after years of promise (still far from inspiring) and (some) regulatory goals to their credit (the Remplir FDA delay and silence on has been awful).

OCC has been a poor investment since IPO (there have been far worse in biotech in the similar era) but is literally is finally delivering on its "i"m excited about the future" promises year after year. If only we'd all ironically been on Vericel in the same period:



I was, in a modest quantity alas, but have recently halved what I held and put the capital into OCC. Hotdog sold OCC to divest into IMU and has alas seen losses there. Feel for the guy, despite the selling pressure he has brought to OCC share price recently. Good luck HD.